The unit is primarily concerned with searching for and validating new diagnostic and prognostic RNA biomarkers for a number of different diseases. It has a range of molecular methods available for the screening and validation process in line with GLP, e.g. next generation sequencing, microarrays, and PCR-based methods. An additional focus lies on accompanying diagnostics, which is viewed as a key step towards personalized healthcare. The team develops specific tests (e.g. for diagnosing cancer) to help them reach this ideal goal.